Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2022-06-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于成都先导药物开发股份有限公司与关联方共同投资设立核酸药物研发公司暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report on a related-party transaction involving the establishment of a new company jointly invested by the listed company and its related parties. It includes descriptions of the transaction, the parties involved, the pricing, the necessity and impact on the company, the board and independent directors' opinions, and the sponsor's (underwriter's) review and conclusion. The document references regulatory rules and compliance with listing rules, but it is not an annual or interim financial report, nor an earnings release or call transcript. It is not a simple announcement but a comprehensive disclosure of a related-party transaction. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure document that does not fit other specific categories like capital update or management change. The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2022-06-30 Chinese
成都先导药物开发股份有限公司关于选举董事长、副董事长、董事会专门委员会委员暨聘任高级管理人员及证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Chengdu Lead Drug Development Co., Ltd. regarding the election of the chairman, vice chairman, board committee members, and the appointment of senior management and securities affairs representatives. It details the results of shareholder meetings and board meetings held in 2022, including the election of directors and appointment of executives. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board and senior management personnel. Therefore, this document fits the category of Board/Management Information (MANG). The document length is about 4754 characters, which is sufficient for a detailed announcement but not a full report.
2022-06-17 Chinese
成都先导药物开发股份有限公司独立董事关于第二届董事会第二次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on several board resolutions regarding the appointment of senior management positions, including the general manager, financial officer, board secretary, and other senior executives. It references compliance with company law, governance rules, and qualifications for these roles. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management appointments and approvals. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and does not indicate it is a report or announcement of a report, so it is not an RPA or RNS.
2022-06-17 Chinese
成都先导药物开发股份有限公司2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from the 2022 first extraordinary shareholders' meeting of Chengdu Lead Drug Development Co., Ltd. It details the meeting date, location, attendance, voting results on various proposals including amendments to the company charter and election of an independent director, and includes a lawyer's witness statement confirming the legality of the meeting and resolutions. This is a formal announcement of voting results from a shareholders' meeting, not a full report or presentation. The content matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not financial or management reports.
2022-06-16 Chinese
北京君合（成都）律师事务所关于成都先导药物开发股份有限公司2022年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and procedures of the 2022 first extraordinary general meeting (临时股东大会) of Chengdu Lead Drug Development Co., Ltd. It details the convening, attendance, voting procedures, and legality of the shareholder meeting and its resolutions. It is not a financial report, earnings release, or management discussion. It is a legal opinion related to a shareholder meeting and the voting results of that meeting. This type of document is best classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the voting results and legality of the shareholder meeting resolutions.
2022-06-16 Chinese
成都先导药物开发股份有限公司2022年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2022 年第一次临时股东大会会议资料" which translates to "2022 First Extraordinary General Meeting (EGM) Meeting Materials". It contains detailed information about the meeting agenda, voting procedures, and proposals to be discussed and voted on during the meeting. The content includes meeting notices, agenda items such as amendments to the company charter and election of an independent director, and instructions for shareholders' participation and voting. This type of document is typically distributed to shareholders prior to or during a general meeting to inform them about the meeting details and proposals. It is not a report of voting results, nor is it a regulatory announcement or a financial report. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2022-06-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.